The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt

Oncogene

Volumn 28, Issue 25, 2009, Pages 2365-2369

  Somanath, P R ^a   Vijai, J ^b   Kichina, J V ^b   Byzova, T ^a   Kandel, E S ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Extracellular signal regulated MAP kinases; Neoplastic cell transformation; P21 activated kinases; Protein kinase B

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; P21 ACTIVATED KINASE; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TUMOR CELL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LUCIFERASES; MAP KINASE SIGNALING SYSTEM; MICE; NIH 3T3 CELLS; P21-ACTIVATED KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF;

EID: 67649958065     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.114     Document Type: Article

References (28)

1. Bereiter-Hahn J, Munnich A, Woiteneck P. (1998). Dependence of energy metabolism on the density of cells in culture. Cell Struct Funct 23: 85-93. Chaudhary A, King WG,MattalianoMD, Frost JA, Diaz B, Morrison
2. DK et al. (2000). Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr Biol 10: 551-554.
3. Euhus DM, Hudd C, LaRegina MC, Johnson FE. (1986). Tumor measurement in the nude mouse. J Surg Oncol 31: 229-234. Galang CK, Garcia-Ramirez JJ, Solski PA, Westwick JK, Der CJ,
4. Neznanov NN et al. (1996). Oncogenic Neu/ErbB-2 increases Ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting Ets activation blocks neu-mediated cellular transformation. J Biol Chem 271: 7992-7998.
5. Galetic I, Maira SM, Andjelkovic M, Hemmings BA. (2003). Negative regulation of ERK and Elk by protein kinase B modulates c-Fos transcription. J Biol Chem 278: 4416-4423.
6. Gartel AL, Kandel ES. (2006). RNA interference in cancer. Biomol Eng 23: 17-34.
7. Kandel ES, Hay N. (1999). The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253: 210-229.
8. Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS et al. (2002). Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22: 7831-7841.
9. Kennedy SG, Kandel ES, Cross TK, Hay N. (1999). Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 19: 5800-5810.
10. King AJ, Sun H, Diaz B, Barnard D, Miao W, Bagrodia S et al. (1998). The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 396: 180-183.
11. Leevers SJ, Paterson HF, Marshall CJ. (1994). Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369: 411-414.
12. McCubrey JA, Lee JT, Steelman LS, Blalock WL,Moye PW, Chang F et al. (2001). Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detect Prev 25: 375-393. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand
13. FE et al. (2006). Roles of the RAF/MEK/ERK and PI3K/PTEN/ AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279. Mirza AM, Gysin S, Malek N, Nakayama K-I, Roberts JM,
14. McMahon M. (2004). Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol 24: 10868-10881.
15. Mirza AM, Kohn AD, Roth RA, McMahon M. (2000). Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. Cell Growth Differ 11: 279-292.
16. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. (2002). Regulation of Raf-Akt cross-talk. J Biol Chem 277: 31099-31106.
17. Morgenstern JP, Land H. (1990). Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res18: 3587-3596.
18. Nheu T, He H, Hirokawa Y, Walker F, Wood J, Maruta H. (2004). PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Cell Cycle 3: 71-74.
19. Roberts PJ, Der CJ. (2007). Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
20. Shelton JG, Blalock WL, White ER, Steelman LS, McCubrey JA. (2004). Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle 3: 503-512.
21. Sheng H, Shao J, DuBois RN. (2001). Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells. J Biol Chem 276: 14498-14504.
22. Somanath PR, Byzova TV. (2009). 14-3-3beta-Rac1-p21 activated kinase signaling regulates Akt1-mediated cytoskeletal organization, lamellipodia formation and fibronectin matrix assembly. J Cell Physiol 218: 394-404.
23. Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF. (1994). Activation of Raf as a result of recruitment to the plasma membrane. Science 264: 1463-1467.
24. Sun H, King AJ, Diaz HB, Marshall MS. (2000). Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak. Current Biology 10: 281-284.
25. Tang Y, Chen Z, Ambrose D, Liu J, Gibbs JB, Chernoff J et al. (1997). Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol 17: 4454-4464.
26. Weinberg RA. (2007). The Biology of Cancer. Garland Science: New York.
27. Yuan TL, Cantley LC. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
28. Zimmermann S, Moelling K. (1999). Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286: 1741-1744.